FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Latvian: Pacientiem ar mēreniem vai smagiem nieru darbības traucējumiem nepieciešama emtricitabīna un tenofovīra disoproksila devu starplaiku pielāgošana, ko nevar panākt ar kombinēto tableti (skatīt 4.2. un 4.4. apakšpunktu).
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following co-administration with efavirenz leading to reduced therapeutic effect of sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir (see section
Latvian: Nav ieteicams vienlaicīgi lietot Efavirenz/Emtricitabine/Tenofovir disoproxil Krka un sofosbuvīru/velpatasvīru vai sofosbuvīru/velpatasvīru/voksilaprevīru, jo ir sagaidāms, ka pēc efavirenza lietošanas velpatasvīra un voksilaprevīra koncentrācija plazmā mazināsies un izraisīs sofosbuvīra/velpatasvīra vai sofosbuvīra/velpatasvīra/voksilaprevīra terapeitiskās ietekmes samazināšanos (skatīt 4.5. apakšpunktu).
English: (20/120 mg tablet, 6 doses of 4 tablets each over 3 days/600 mg q.d.)
Latvian: Pretmalārijas līdzekļi Artemeters/lumefantrīns/efavirenzs (20/120 mg tabletes, 6 devas ar 4 tabletēm katrā, 3 dienu laikā/600 mg q.d.)
English: Each film-coated tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil (as succinate).
Latvian: Katra apvalkotā tablete satur 600 mg efavirenza, 200 mg emtricitabīna un 245 mg tenofovīra disoproksila (sukcināta veidā).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may reduce the amount of atovaquone/proguanil or artemether/lumefantrine in your blood.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka var samazināt atovakvona/proguanila vai artemetera/lumefantrīna daudzumu Jūsu asinīs.
English: Indinavir/Tenofovir disoproxil (800 mg q8h/245 mg q.d.)
Latvian: Indinavīrs/tenofovīra disoproksils (800 mg q8h/245 mg q.d.)
English: M184V/I K65R K70E TAMs
Latvian: M184V/I
English: Sofosbuvir: AUC: ↔ Cmax: ↔ GS331007 AUC: ↔ Cmax: ↔ Cmin: ↔
Latvian: AUC: ↔ Cmax: ↔ GS331007 AUC: ↔ Cmax: ↔ Cmin: ↔
English: Rashes may be caused by Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Izsitumus varētu būt izraisījusi Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: The following side effects are rare (these may affect up to 1 in every 1,000 patients)
Latvian: Šādas blakusparādības ir retas (var skart līdz 1 no katriem 1 000 pacientiem)
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is to be used in combination with darunavir/ritonavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used.
Latvian: Ja Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka ir jālieto kopā ar darunavīru/ritonavīru, jālieto ārstēšanas shēma ar 600/100 mg darunavīra/ritonavīra divas reizes dienā.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may cause dizziness, impaired concentration and drowsiness.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka var izraisīt reiboni, traucēt koncentrēšanās spējas un izraisīt miegainību.
English: Rifampicin/Tenofovir disoproxil (600 mg q.d./245 mg q.d.)
Latvian: Rifampicīns/tenofovīra disoproksils (600 mg q.d./245 mg q.d.)
English: Maraviroc/Tenofovir disoproxil (300 mg b.i.d./245 mg q.d.)
Latvian: Maraviroks/tenofovīra disoproksils (300 mg b.i.d./245 mg q.d.)
English: Co-administration of standard doses of efavirenz and voriconazole is contraindicated (see section 4.3).
Latvian: Efavirenza un vorikonazola vienlaikus lietošana standarta devās ir kontrindicēta (skatīt 4.3. apakšpunktu).
English: The administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 5.2).
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošana kopā ar pārtiku var palielināt efavirenza iedarbību un var radīt blakusparādību biežuma pieaugumu (skatīt 4.4. un 5.2. apakšpunktu).
English: vomiting,
Latvian: proteinūrija,
English: If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is stopped, speak to your doctor before you restart taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tablets.
Latvian: Ja Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošana ir pārtraukta, pirms tablešu lietošanas atsākšanas konsultējieties ar ārstu.
English: While the clinical significance of decreased indinavir concentrations has not been established, the magnitude of the observed pharmacokinetic interaction should be taken into consideration when choosing a regimen containing both efavirenz, a component of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, and indinavir.
Latvian: Tā kā indinavīra koncentrācijas samazināšanās klīniskā nozīme nav noteikta, jāņem vērā novērotās farmakokinētiskās mijiedarbības nozīme, ja izvēlas terapijas shēmu, kas satur gan efavirenzu,
English: Therefore co-administration of atazanavir/ritonavir and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended (see Table 1).
Latvian: Tādēļ atazanavīru/ritonavīru un Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kopā lietot neiesaka (skatīt 1. tabulu).
English: The clinical significance of these effects is
Latvian: Šīs iedarbības klīniskā nozīme nav zināma.
English: Tacrolimus/Emtricitabine/Tenofovi r disoproxil (0.1 mg/kg q.d./200 mg/245 mg q.d.)
Latvian: Takrolīms/emtricitabīns/tenofovīra disoproksils (0.1 mg/kg q.d./200 mg/245 mg q.d.)
English: Tacrolimus: AUC: ↔ Cmax: ↔ C24h: ↔
Latvian: Takrolīms: AUC: ↔ Cmax: ↔ C24h: ↔
English: Gastrointestinal disorders: Very common diarrhoea, nausea diarrhoea,
Latvian: Kuņģa-zarnu trakta traucējumi: Ļoti bieži diareja, slikta dūša diareja, vemšana, slikta dūša
English: dizziness has been reported during treatment with efavirenz, emtricitabine and tenofovir disoproxil.
Latvian: Tomēr ārstēšanas laikā ar efavirenzu, emtricitabīnu un tenofovīra disoproksilu ziņots par reiboni.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg apvalkotās tabletes
English: Concomitant administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/ voxilaprevir is expected to decrease plasma concentrations of velpatasvir and voxilaprevir.
Latvian: Ir sagaidāms, ka pēc vienlaicīgas Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka un sofosbuvīra/velpatasvīra vai sofosbuvīra/velpatasvīra/ voksilaprevīra lietošanas, velpatasvīra un voksilaprevīra koncentrācija plazmā mazināsies.
English: Renal function should be closely monitored (see section
Latvian: Stingri jākontrolē nieru darbība (skatīt 4.4. apakšpunktu).
English: Barrier contraception should always be used in combination with other methods of contraception (for example, oral or other hormonal contraceptives, see section 4.5) while on therapy with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka terapijas laikā vienmēr vienlaikus ar citiem kontracepcijas līdzekļiem (piemēram, perorālajiem vai citiem hormonālās kontracepcijas līdzekļiem, skatīt 4.5. apakšpunktu) jāizmanto kontracepcijas barjermetode.
English: The following side effects are rare (these may affect up to 1 in every 1,000 patients):
Latvian: Šādas blakusparādības ir retas (var rasties līdz 1 no katriem 1 000 pacientiem):
English: Atazanavir:
Latvian: Itrakonazols:
English: Ethinyloestradiol+Norgestimate/Ef avirenz (0.035 mg+0.25 mg q.d./600 mg q.d.)
Latvian: Norgestimāts/efavirenzs (0.035 mg+0.25 mg q.d./600 mg q.d.)
English: , neurosis
Latvian: , murgi neiroze
English: When co-administered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, sertraline dose increases should be guided by clinical response.
Latvian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka lieto kopā ar sertralīnu, atkarībā no klīniskās atbildes reakcijas jāpalielina sertralīna devas.
English: Dose adjustments of calcium channel blockers when coadministered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
Latvian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, deva jāpielāgo atbilstoši klīniskās atbildes reakcijai (skatīt kalcija kanālu blokatoru zāļu aprakstu).
English: Use of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should be avoided with concurrent or recent use of a nephrotoxic medicinal product.
Latvian: Jāizvairās no Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošanas, ja vienlaikus vai nesen lietoti nefrotoksiski medikamenti.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of statins in your blood.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka var samazināt statīnu daudzumu Jūsu asinīs.
English: Uncommon rhabdomyolysis muscular weakness
Latvian: Retāk rabdomiolīze muskuļu vājums
English: The following side effects are common (these may affect up to 1 in 10 patients)
Latvian: Šādas blakusparādības ir biežas (var rasties līdz 1 no 10 pacientiem)
English: Insufficient data are available to make a dosing recommendation for indinavir when dosed with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Latvian: Dati nav pietiekami, lai noteiktu dozēšanas rekomendācijas indinavīram kopā ar Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: particularly in patients with underlying systemic or renal disease, or in patients taking nephrotoxic agents.
Latvian: Iespējams būs jākontrolē nieru darbība, īpaši pacientiem, kuriem ir sistēmiska vai nieru slimība, vai
English: Other medicines and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Latvian: Citas zāles un Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
English: If the patient vomits more than 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka he/she does not need to take another dose.
Latvian: Ja pacientam sākas vemšana vairāk nekā 1 stundu pēc Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošanas, otra deva nav jālieto.
English: Reproductive system and breast disorders: Uncommon gynaecomastia
Latvian: Reproduktīvās sistēmas traucējumi un krūts slimības: Retāk ginekomastija
English: Norgestimate/Ethinyloestradiol/ Emtricitabine
Latvian: Norgestimāts/Etinilestradiols/
English: Recommendation concerning co-administration with Efavirenz/Emtricitabine/Tenof ovir disoproxil Krka (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Latvian: Ieteikumi lietošanai kopā ar Efavirenz/Emtricitabine/Tenofo vir disoproxil Krka (efavirenzs 600 mg,
English: Emtricitabine and tenofovir disoproxil
Latvian: Emtricitabīna un tenofovīra disoproksils
English: Lopinavir/ritonavir/Tenofovir disoproxil (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)
Latvian: Lopinavīrs/ritonavīrs/tenofovīra disoproksils (400 mg b.i.d./100 mg b.i.d./245 mg q.d.)
English: The pharmacokinetics of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka > have not been studied in patients with hepatic impairment.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka farmakokinētika pacientiem ar aknu darbības traucējumiem nav pētīta.
English: Co-administration of ritonavir at doses of 600 mg and Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is not recommended.
Latvian: Ritonavīra 600 mg devas un Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka kopā lietot neiesaka.
English: AUC12h: ↔ Cmax: ↔
Latvian: Maraviroks: AUC12h: ↔ Cmax: ↔
English: If you take more Efavirenz/Emtricitabine/Tenofovir disoproxil Krka than you should
Latvian: Ja esat lietojis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka vairāk nekā noteikts
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka can reduce the amount of itraconazole or posaconazole in your blood.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka var samazināt itrakonazola vai posakonazola daudzumu Jūsu asinīs.
English: It is recommended that Efavirenz/Emtricitabine/Tenofovir disoproxil Krka be taken on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Latvian: Efavirenzu/emtricitabīnu/tenofovīra disoproksilu ieteicams lietot tukšā dūšā, jo pārtika var pastiprināt efavirenza iedarbību un var izraisīt blakusparādību biežuma palielināšanos (skatīt 4.4. un 4.8. apakšpunktu).
English: United Kingdom Consilient Health (UK) Ltd. Tel: +44 (0)203 751 1888
Latvian: Tel: +44 (0) 203 751 1888
English: The administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in frequency of adverse reactions (see section 4.8).
Latvian: Lietojot Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kopā ar pārtiku, var pastiprināties efavirenza iedarbība (skatīt 5.2. apakšpunktu) un var pieaugt nevēlamo blakusparādību biežums (skatīt 4.8. apakšpunktu).
English: Efavirenz/emtricitabine/tenofovir disoproxil is recommended for administration on an empty stomach since food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see sections 4.4 and 4.8).
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietot iesaka tukšā dūšā, jo pārtikas produkti var pastiprināt efavirenza iedarbību un var palielināt nevēlamo blakusparādību biežumu (skatīt 4.4. un 4.8. apakšpunktu).
English: It is important not to miss a dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Ir svarīgi, lai Jūs neizlaistu nevienu Efavirenz/Emtricitabine/Tenofovir disoproxil Krka devu.
English: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Latvian: AUC: ↑ 11% (↑ 5 līdz ↑ 18) Cmax: ↑ 16% (↑ 6 līdz ↑ 26) Cmin: ↑ 13% (↑ 1 līdz ↑ 26) (CYP3A4 indukcija) Efavirenza farmakokinētikas rādītāju pieaugums nav klīniski nozīmīgs.
English: Pharmacokinetic studies have not been performed with efavirenz, emtricitabine or tenofovir in elderly patients (over 65 years of age).
Latvian: Vecums Gados vecākiem pacientiem (vairāk kā 65 gadus veciem) efavirenza, emtricitabīna vai tenofovīra farmakokinētikas pētījumi nav veikti.
English: This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil.
Latvian: Šī blakusparādība tika identificēta efavirenza, emtricitabīna vai tenofovīra disoproksila pēcreģistrācijas novērošanas laikā.
English: When
Latvian: Tā kā
English: You must remain under the care of your doctor while taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Jums joprojām jāpaliek ārsta uzraudzībā Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošanas laikā.
English: Efavirenz: AUC: ↔ Cmax: ↔
Latvian: Efavirenzs: AUC: ↔ Cmax: ↔
English: Ethinyloestradiol: AUC: ↔ Cmax: ↔
Latvian: Etinilestradiols: AUC: ↔ Cmax: ↔
English: Fosamprenavir/ritonavir/Emtricitab ine
Latvian: Fosamprenavīrs/ritonavīrs/emtricita bīns
English: Indinavir/Efavirenz (800 mg q8h/200 mg q.d.)
Latvian: Indinavīrs/efavirenzs (800 mg q8h/200 mg q.d.)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may affect your kidneys.
Latvian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka var ietekmēt nieru darbību.
English: Cmax: ↓ 37% (↓ 20 to ↓ 51) Cmin: ↓ 44% (↓ 27 to ↓ 58) (decrease in itraconazole concentrations: CYP3A4 induction)
Latvian: AUC: ↓ 39% (↓ 21 līdz ↓ 53) Cmax: ↓ 37% (↓ 20 līdz ↓ 51) Cmin: ↓ 44% (↓ 27 līdz ↓ 58) (itrakonazola koncentrācijas pazemināšanās: CYP3A4 indukcija)
English: Rifampicin/Efavirenz (600 mg q.d./600 mg q.d.)
Latvian: Rifampicīns/Efavirenzs (600 mg q.d./600 mg q.d.)
English: Emtricitabine: AUC: ↔ Cmax: ↔
Latvian: Emtricitabīns: AUC: ↔ Cmax: ↔
English: Rifampicin: AUC: ↔ Cmax: ↔
Latvian: Rifampicīns: AUC: ↔ Cmax: ↔
English: If you forget to take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Latvian: Ja esat aizmirsis lietot Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Latvian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka sastāvdaļu, gan indinavīru.
English: If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is co-administered with an NSAID, renal function should be monitored adequately.
Latvian: Lietojot Efavirenz/Emtricitabine/Tenofovir disoproxil Krka vienlaikus ar NPL, atbilstoši jāpārbauda nieru darbība.
English: Table 2: Adverse reactions associated with efavirenz/emtricitabine/tenofovir disoproxil listed by the component(s) of efavirenz/emtricitabine/tenofovir disoproxil to which the adverse reactions are attributable
Latvian: Efavirenza/emtricitabīna/ tenofovīra disoproksila blakusparādības, kas uzskaitītas atbilstoši saistībai ar efavirenza/emtricitabīna/ tenofovīra disoproksila sastāvdaļu(-ām).
English: The following side effects are uncommon (these may affect up to 1 in every 100 patients):
Latvian: Šādas blakusparādības ir retākas (var rasties līdz 1 no katriem 100 pacientiem):
English: Saquinavir/ritonavir/Tenofovir disoproxil
Latvian: Sakvinavīrs/ritonavīrs/tenofovīra disoproksils
English: Fosamprenavir/ritonavir/Efavirenz (700 mg b.i.d./100 mg b.i.d./600 mg q.d.)
Latvian: Fosamprenavīrs/ritonavīrs/efaviren zs (700 mg b.i.d./100 mg b.i.d./600 m g q.d.)
English: Symptoms including, but not limited to, dizziness, insomnia, somnolence, impaired concentration and abnormal dreaming are frequently reported undesirable effects in patients receiving efavirenz 600 mg daily in clinical studies.
Latvian: Pacientiem, kuri klīniskajos pētījumos saņēma 600 mg efavirenza dienā, bieži novēroja tālāk tādas, bet un ne tikai, nelabvēlīgas blakusparādības kā reiboni, bezmiegu, miegainību, traucētas koncentrēšanās spējas un murgainus sapņus.
English: Since Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is a fixed-dose combination product, the dose of efavirenz cannot be altered; therefore, voriconazole and Efavirenz/Emtricitabine/Tenofovir disoproxil
Latvian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka ir fiksētu devu kombinācija, efavirenza devu nevar mainīt; tādēļ vorikonazolu un
English: If the patient vomits within 1 hour of taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, another tablet should be taken.
Latvian: Ja 1 stundas laikā pēc Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ieņemšanas pacientam sākas vemšana, ir jālieto otra tablete.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended for patients with moderate or severe renal impairment (creatinine clearance (CrCl) < 50 ml/min).
Latvian: Neiesaka lietot Efavirenz/Emtricitabine/Tenofovir disoproxil Krka pacientiem ar mēreniem vai smagiem nieru darbības traucējumiem (kreatinīna klīrenss (CrCl) < 50 ml/min).
English: Rare completed suicide delusion
Latvian: Retāk pašnāvības mēģinājumi domas par pašnāvību psihoze
English: A single 245 mg dose of tenofovir disoproxil was administered to non-HIV infected patients with varying degrees of hepatic impairment defined according to CPT classification.
Latvian: Ar HIV neinficētiem pacientiem, kuriem bija dažādas pakāpes aknu darbības traucējumi atbilstoši CPT klasifikācijai, ordinēja 245 mg tenofovīra disoproksila reizes devu.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should be administered with caution to elderly patients (see section 4.4).
Latvian: Gados vecākiem pacientiem Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ir jānozīmē piesardzīgi (skatīt 4.4. apakšpunktu).
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and vigabatrin or gabapentin can be coadministered without dose adjustment.
Latvian: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka kopā ar vigabatrīnu vai gabapentīnu, deva nav jāpielāgo.
English: DMPA/Tenofovir disoproxil
Latvian: DMPA/tenofovīra disoproksils
English: Administration to patients with: a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms, or with any other clinical condition known to prolong the QTc interval.
Latvian: Lietošana pacientiem ar: - pēkšņas nāves vai iedzimtu QTc intervāla pagarināšanos elektrokardiogrammā ģimenes anamnēzē, vai kādu citu klīnisko stāvokli, kas zināms kā QTc intervālu pagarinošs, - simptomātisku sirds aritmiju anamnēzē vai ar klīniski nozīmīgu bradikardiju, vai sastrēguma sirds mazspēju, ko papildina samazināta kreisā kambara izsviedes frakcija, - smagiem elektrolītu līdzsvara traucējumiem, piem., hipokaliēmiju vai hipomagnēmiju.
English: Simeprevir/Tenofovir disoproxil (150 mg q.d./245 mg q.d.)
Latvian: Simeprevīrs/tenofovīra disoproksils (150 mg q.d./245 mg q.d.)
English: Darunavir/ritonavir should be used with caution in combination with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Latvian: Rifampicīna deva nav jāpielāgo, ja to lieto kopā ar Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: AUC: ↓ 34% (↓ 41 to ↓ 25) Cmax: ↓ 34% (↓ 41 to ↑ 25)
Latvian: AUC: ↓ 34% (↓ 41 līdz ↓ 25) Cmax: ↓ 34% (↓ 41 līdz ↑ 25) Cmin: ↓ 34% (↓ 43 līdz ↑ 24)
English: No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.
Latvian: Nav pieejami dati par efavirenza/emtricitabīna/tenofovīra disoproksila lietošanu kopā ar citiem pretretrovīrusu līdzekļiem.
English: Saquinavir/ritonavir/Emtricitabine Interaction not studied.
Latvian: Sakvinavīrs/ritonavīrs/emtricitabīns Mijiedarbība nav pētīta.
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should not be administered concomitantly with lamivudine (see section 4.4).
Latvian: Ņemot vērā lamivudīna un Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka sastāvdaļas emtricitabīna līdzību, Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka nedrīkst lietot vienlaikus ar lamivudīnu (skatīt 4.4. apakšpunktā).
English: Simvastatin/Tenofovir disoproxil
Latvian: Simvastatīns/tenofovīra disoproksils
English: Since
Latvian: I
English: How to store Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
Latvian: Kā uzglabāt Efavirenz/Emtricitabine/Tenofovir disoproxil Krka
English: Atazanavir/ritonavir
Latvian: Atazanavīrs/ritonavīrs
English: potentiate adverse reactions associated with tenofovir disoproxil, including renal disorders.
Latvian: Palielināta pakļaušana tenofovīra iedarbībai varētu pastiprināt ar tenofovīra disoproksilu saistītas nevēlamās blakusparādības, tostarp nieru darbības
English: This adverse reaction may occur as a consequence of proximal renal tubulopathy.
Latvian: Šī blakusparādība var būt kā proksimālās nieru tubulopātijas sekas.
English: Methadone: AUC: ↓ 52% (↓ 33 to ↓ 66)
Latvian: Atovakvons: AUC: ↓ 75% (↓ 62 līdz ↓ 84)
English: studied in combination with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
Latvian: vienlaicīgas lietošanas ar Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: Do not breast-feed during treatment with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Latvian: Nebarojiet bērnu ar krūti Efavirenz/Emtricitabine/Tenofovir disoproxil Krka lietošanas laikā.
English: AUC: ↓ 69% (↓ 55 to ↓ 79) Cmax: ↓ 60% (↓ 50 to ↓ 68) Cmin: ↓ 63% (↓ 44 to ↓ 75)
Latvian: AUC: ↓ 69% (↓ 55 līdz ↓ 79) Cmax: ↓ 60% (↓ 50 līdz ↓ 68)
English: However,
Latvian: tostarp
English: Artemether/Lumefantrine/Tenofovi r disoproxil
Latvian: Artemeters/lumefantrīns/tenofovīra disoproksils
English: Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir in combination with efavirenz/emtricitabine/tenofovir disoproxil.
Latvian: Dati nav pietiekami, lai noteiktu dozēšanas rekomendācijas sakvinavīram/ritonavīram kopā ar Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka.
English: Methadone: AUC: ↔ Cmax: ↔ Cmin: ↔
Latvian: Metadons: AUC: ↔ Cmax: ↔ Cmin: ↔
English: * When compared to atazanavir 300 mg/ritonavir 100 mg q.d.
Latvian: * Salīdzinot ar atazanavīra 300 mg/ritonavīra 100 mg q.d. lietošanu vakarā bez efavirenza.
English: Tenofovir: AUC: ↔ Cmax: ↔
Latvian: Tenofovīrs: AUC: ↔ Cmax: ↔